Clovis Oncology Inc. (CLVS)

47.52
0.75 1.60
NASDAQ : Health Technology
Prev Close 48.27
Open 48.27
Day Low/High 47.38 / 48.30
52 Wk Low/High 41.72 / 99.45
Volume 693.02K
Avg Volume 1.38M
Exchange NASDAQ
Shares Outstanding 52.55M
Market Cap 2.61B
EPS -7.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Two Oncology Stocks I Like Now

Two Oncology Stocks I Like Now

M&A activity should pick up in the biotech space.

Some Biotech Stocks to Add Exposure To

Some Biotech Stocks to Add Exposure To

Secondary offerings create buying opportunities.

3 Potential Biotech Buyout Targets in the Second Quarter

3 Potential Biotech Buyout Targets in the Second Quarter

Novartis' deal for AveXis has ignited a rally in other gene-therapy concerns.

Possible Biotech Takeout Plays

Possible Biotech Takeout Plays

A look at possible second-quarter M&A activity in the biotech sector.

Infographic: Understanding Ovarian Cancer (Graphic: Business Wire)

Infographic: Understanding Ovarian Cancer (Graphic: Business Wire)

Clovis Oncology, Inc. (NASDAQ:CLVS) today announced that the U.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: GSM, RSPP, SVM, TDS Downgrades: AG, BGS, DJCO, EVC, GLRE, TCP Initiations: CLVS Read on to get TheStreet Quant Ratings' detailed report:

Clovis Oncology Initiates Early Access Program For Rucaparib As Treatment And As Maintenance Therapy In Recurrent Ovarian Cancer In Europe

Clovis Oncology Initiates Early Access Program For Rucaparib As Treatment And As Maintenance Therapy In Recurrent Ovarian Cancer In Europe

Clovis Oncology, Inc. (NASDAQ:CLVS) today announced the initiation of an early access program in Europe for rucaparib for treatment and as maintenance therapy in recurrent ovarian cancer.

CHMP Grants Positive Opinion For Clovis Oncology's Rubraca® (rucaparib) Tablets

CHMP Grants Positive Opinion For Clovis Oncology's Rubraca® (rucaparib) Tablets

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Union's (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the...

Which Hot Biotech Name Will Be Acquired Next?

Which Hot Biotech Name Will Be Acquired Next?

Your burning biotech questions answered in our latest mailbag.

Bret Jensen's Biotech Mailbag

Bret Jensen's Biotech Mailbag

We'll answer two of the common questions we have received so far in March.

Clovis Oncology Announces Notice Of Allowance For Rucaparib High Dosage Strength Tablet Patent With Expiration In 2035

Clovis Oncology Announces Notice Of Allowance For Rucaparib High Dosage Strength Tablet Patent With Expiration In 2035

Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that the Company has received a Notice of Allowance from the United States Patent and Trademark Office in United States Patent Application 14/828,065 with claims...

Clovis Oncology To Present At The Barclays Global Healthcare Conference

Clovis Oncology To Present At The Barclays Global Healthcare Conference

Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Patrick J.

Clovis Oncology Announces 2017 Operating Results

Clovis Oncology Announces 2017 Operating Results

Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter and year ended December 31, 2017, and provided an update on the Company's clinical development programs and regulatory and commercial...

Clovis Oncology Receives Positive Trend Vote From CHMP In European Regulatory Review For Rucaparib Ovarian Cancer Treatment Indication

Clovis Oncology Receives Positive Trend Vote From CHMP In European Regulatory Review For Rucaparib Ovarian Cancer Treatment Indication

Clovis Oncology, Inc. (NASDAQ: CLVS) announced today an update to the ongoing regulatory review for the Marketing Authorization Application (MAA) for rucaparib tablets as monotherapy for the treatment of a limited...

Clovis Oncology To Announce Fourth Quarter And Full Year 2017 Financial Results And Host Webcast Conference Call On February 26

Clovis Oncology To Announce Fourth Quarter And Full Year 2017 Financial Results And Host Webcast Conference Call On February 26

Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its fourth quarter and full year 2017 financial results on Monday, February 26, 2018, after the close of the U.

Five Rules for This Market Beast: Cramer's 'Mad Money' Recap (Tues 1/16/18)

Five Rules for This Market Beast: Cramer's 'Mad Money' Recap (Tues 1/16/18)

Even with Monday's sharp reversal, Jim Cramer says he still likes this market.

Clovis Oncology To Present At The 36th Annual J.P. Morgan Healthcare Conference

Clovis Oncology To Present At The 36th Annual J.P. Morgan Healthcare Conference

Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its Chief Executive Officer and President, Patrick J.

Rucaparib MAA For The Ovarian Cancer Treatment Indication Referred By CHMP To Scientific Advisory Group On Oncology For Review Expected In February 2018

Rucaparib MAA For The Ovarian Cancer Treatment Indication Referred By CHMP To Scientific Advisory Group On Oncology For Review Expected In February 2018

Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that the European Union's (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has requested that the Scientific Advisory Group...

Clovis Up on Priority Review Status for Ovarian Cancer Therapy -- Biotech Mover

Clovis Up on Priority Review Status for Ovarian Cancer Therapy -- Biotech Mover

The FDA has accepted the Boulder, Colo.-based firm's supplemental New Drug Application for ovarian cancer therapy rucaparib and granted priority review status to the application.

Clovis Announces Priority Review Designation For Rucaparib Supplemental New Drug Application

Clovis Announces Priority Review Designation For Rucaparib Supplemental New Drug Application

Clovis Oncology (NASDAQ: CLVS) announced today that the U.S.

Clovis Oncology To Present At The Stifel 2017 Healthcare Conference

Clovis Oncology To Present At The Stifel 2017 Healthcare Conference

Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its Chief Executive Officer and President, Patrick J.

Notable Thursday Option Activity: CLVS, GOGO, ENDP

Notable Thursday Option Activity: CLVS, GOGO, ENDP

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Clovis Oncology Inc , where a total of 5,548 contracts have traded so far, representing approximately 554,800 underlying shares. That amounts to about 47.9% of CLVS's average daily trading volume over the past month of 1.2 million shares.

Clovis Oncology Announces Third Quarter 2017 Operating Results

Clovis Oncology Announces Third Quarter 2017 Operating Results

Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended September 30, 2017, and provided an update on the Company's clinical development programs and regulatory outlook for the remainder...

Clovis Oncology To Announce Third Quarter 2017 Financial Results And Host Webcast Conference Call On November 1

Clovis Oncology To Announce Third Quarter 2017 Financial Results And Host Webcast Conference Call On November 1

Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its third quarter 2017 financial results on Wednesday, November 1, 2017, after the close of the U.

What's Hot and What's Not: Cramer's 'Mad Money' Recap (Thursday 10/12/17)

What's Hot and What's Not: Cramer's 'Mad Money' Recap (Thursday 10/12/17)

In this sometimes fickle market, supply and demand are still at play.

TheStreet Quant Rating: D- (Sell)